$7.185
-0.015[-0.21%]
Last update: 2:50PM Get Real Time Here
GoodRx Holdings
(NASDAQ:GDRX)GoodRx Holdings Stock (NASDAQ:GDRX), Analyst Ratings, Price Targets, Predictions
GoodRx Holdings Inc has a consensus price target of $10.93, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, Barclays, and Raymond James on May 23, 2024, May 20, 2024, and May 16, 2024. With an average price target of $10 between RBC Capital, Barclays, and Raymond James, there's an implied 39.18% upside for GoodRx Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Barclays
Raymond James
TD Cowen
Keybanc
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for GoodRx Holdings
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/23/2024 | Buy Now | 39.18% | RBC Capital | Mark Mahaney | $8 → $10 | Upgrade | Sector Perform → Outperform | Get Alert |
| 05/20/2024 | Buy Now | 39.18% | Barclays | Stephanie Davis | $9 → $10 | Maintains | Overweight | Get Alert |
| 05/16/2024 | Buy Now | 39.18% | Raymond James | John Ransom | → $10 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/16/2024 | Buy Now | 122.69% | TD Cowen | Charles Rhyee | $14 → $16 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | 25.26% | Keybanc | Scott Schoenhaus | → $9 | Upgrade | Sector Weight → Overweight | Get Alert |
| 03/25/2024 | Buy Now | 39.18% | Wells Fargo | Stan Berenshteyn | → $10 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 03/08/2024 | Buy Now | 11.34% | RBC Capital | Sean Dodge | → $8 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/01/2024 | Buy Now | 4.38% | Wells Fargo | Stan Berenshteyn | $6 → $7.5 | Maintains | Equal-Weight | Get Alert |
| 03/01/2024 | Buy Now | 11.34% | UBS | Eric Sheridan | $5 → $8 | Maintains | Neutral | Get Alert |
| 03/01/2024 | Buy Now | 11.34% | RBC Capital | Sean Dodge | $7 → $8 | Maintains | Sector Perform | Get Alert |
| 03/01/2024 | Buy Now | 4.38% | Goldman Sachs | Eric Sheridan | $6.5 → $7.5 | Maintains | Neutral | Get Alert |
| 03/01/2024 | Buy Now | 11.34% | Truist Securities | Jailendra Singh | $7.5 → $8 | Maintains | Hold | Get Alert |
| 03/01/2024 | Buy Now | 94.85% | TD Cowen | Charles Rhyee | $12 → $14 | Maintains | Outperform | Get Alert |
| 03/01/2024 | Buy Now | 39.18% | JP Morgan | Lisa Gill | $7 → $10 | Upgrade | Neutral → Overweight | Get Alert |
| 03/01/2024 | Buy Now | 25.26% | Barclays | Steve Valiquette | $8 → $9 | Maintains | Overweight | Get Alert |
| 02/26/2024 | Buy Now | 11.34% | Leerink Partners | Michael Cherny | → $8 | Initiates | → Outperform | Get Alert |
| 01/16/2024 | Buy Now | -2.57% | RBC Capital | Sean Dodge | $5 → $7 | Maintains | Sector Perform | Get Alert |
| 01/12/2024 | Buy Now | 4.38% | Truist Securities | Jailendra Singh | $5.5 → $7.5 | Maintains | Hold | Get Alert |
| 01/02/2024 | Buy Now | -37.37% | B of A Securities | Michael Cherny | $8 → $4.5 | Downgrade | Buy → Underperform | Get Alert |
| 11/17/2023 | Buy Now | -16.49% | JP Morgan | Doug Anmuth | $7 → $6 | Maintains | Neutral | Get Alert |
| 11/13/2023 | Buy Now | -16.49% | Goldman Sachs | Eric Sheridan | $7 → $6 | Maintains | Neutral | Get Alert |
| 11/10/2023 | Buy Now | -30.41% | RBC Capital | Sean Dodge | $8 → $5 | Maintains | Sector Perform | Get Alert |
| 11/10/2023 | Buy Now | -16.49% | Goldman Sachs | Eric Sheridan | $7 → $6 | Maintains | Neutral | Get Alert |
| 11/10/2023 | Buy Now | -23.45% | Truist Securities | Jailendra Singh | $8 → $5.5 | Maintains | Hold | Get Alert |
| 11/10/2023 | Buy Now | -23.45% | Morgan Stanley | Ricky Goldwasser | $8 → $5.5 | Maintains | Equal-Weight | Get Alert |
| 09/14/2023 | Buy Now | -2.57% | JP Morgan | Doug Anmuth | $6 → $7 | Maintains | Neutral | Get Alert |
| 08/11/2023 | Buy Now | -2.57% | Goldman Sachs | Eric Sheridan | $6.25 → $7 | Maintains | Neutral | Get Alert |
| 08/10/2023 | Buy Now | 11.34% | Deutsche Bank | George Hill | $6 → $8 | Maintains | Hold | Get Alert |
| 08/10/2023 | Buy Now | 39.18% | Guggenheim | Sandy Draper | $8 → $10 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | -16.49% | JP Morgan | Doug Anmuth | $5 → $6 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for GoodRx Holdings (GDRX)?
The latest price target for GoodRx Holdings (NASDAQ: GDRX) was reported by RBC Capital on May 23, 2024. The analyst firm set a price target for $10.00 expecting GDRX to rise to within 12 months (a possible 39.18% upside). 41 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for GoodRx Holdings (GDRX)?
The latest analyst rating for GoodRx Holdings (NASDAQ: GDRX) was provided by RBC Capital, and GoodRx Holdings upgraded their outperform rating.
When was the last upgrade for GoodRx Holdings (GDRX)?
The last upgrade for GoodRx Holdings Inc happened on May 23, 2024 when RBC Capital raised their price target to $10. RBC Capital previously had a sector perform for GoodRx Holdings Inc.
When was the last downgrade for GoodRx Holdings (GDRX)?
The last downgrade for GoodRx Holdings Inc happened on January 2, 2024 when B of A Securities changed their price target from $8 to $4.5 for GoodRx Holdings Inc.
When is the next analyst rating going to be posted or updated for GoodRx Holdings (GDRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GoodRx Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GoodRx Holdings was filed on May 23, 2024 so you should expect the next rating to be made available sometime around May 23, 2025.
Is the Analyst Rating GoodRx Holdings (GDRX) correct?
While ratings are subjective and will change, the latest GoodRx Holdings (GDRX) rating was a upgraded with a price target of $8.00 to $10.00. The current price GoodRx Holdings (GDRX) is trading at is $7.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.